Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021; 23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021; 23(8):E631-638. doi:
10.1001/amajethics.2021.631.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021; 23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Dr Donna-Bea Tillman joins Ethics Talk to discuss her article: "What Should the Public Know About Implantable Material and Device Innovation in the US?"